dexlansoprazole + levosulpiride

A **combination drug** containing dexlansoprazole, a proton pump inhibitor (PPI), and levosulpiride, a prokinetic and antipsychotic agent. Dexlansoprazole reduces gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase (the proton pump) on gastric parietal cells, providing acid suppression for the treatment of conditions like GERD and erosive esophagitis. Levosulpiride acts as a selective antagonist at dopamine D2 receptors in the enteric nervous system, enhancing gastrointestinal motility and accelerating gastric emptying. The drug is primarily indicated for **gastroesophageal reflux disease (GERD)**, **peptic ulcers**, **functional dyspepsia**, and other acid-related and motility disorders of the upper digestive tract[1][3][5]. It is administered orally, typically used in adults, and is not recommended for children[1]. The combination is not a steroid and is contraindicated in patients with hypersensitivity to the components, GI hemorrhage, mechanical obstruction, or perforation[1].